IP Library Granted Patent US 9,963,505
Granted Patent B2
US 9,963,505 · App. 15/094,211 · Granted May 8, 2018

Anti-human folate receptor beta antibodies and methods of use

Inventors: Philip S. Low (West Lafayette, IN); Dimiter S. Dimitrov (Frederick, MD); Yang Feng (Frederick, MD); Jiayin Shen (San Diego, CA)
Assignee: PURDUE RESEARCH FOUNDATION
C07K16/28A61K9/0019A61K9/127A61K38/00A61K47/48561A61K47/48823A61K49/0058A61K49/16A61K51/1027C07K14/705C07K2317/21C07K2317/33C07K2317/54C07K2317/565C07K2317/732C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,963,505
App. No.
15/094,211
Granted
May 8, 2018
Kind
B2
Abstract

Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ.

Claims (14)

1. A method of treating a patient having an inflammatory disorder, said method comprising administering to said patient an amount of an isolated human monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds human folate receptor beta (FRβ) effective to reduce the number of FRβ positive macrophages and FRβ positive monocytes in said patient, wherein the antibody or fragment comprises

a heavy chain variable region (V H ) complementarity determining region (CDR) 1 comprising the amino acid sequence set forth in SEQ ID NO:1;

a V H CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2;

a V H CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3;

a light chain variable region (V L ) CDR1 comprising the amino acid sequence set forth in SEQ ID NO:4;

a V L CDR2 comprising the amino acid sequence set forth in SEQ ID NO:5; and

a V L CDR3 comprising the amino acid sequence set forth in SEQ ID NO:6; or

wherein the antibody or fragment comprises

a V H CDR1 comprising the amino acid sequence set forth in SEQ ID NO:1;

a V H CDR2 comprising the amino acid sequence set forth in SEQ ID NO:2;

a V H CDR3 comprising the amino acid sequence set forth in SEQ ID NO:3;

a V L CDR1 comprising the amino acid sequence set forth in SEQ ID NO:14;

a V L CDR2 comprising the amino acid sequence set forth in SEQ ID NO:15; and

a V L CDR3 comprising the amino acid sequence set forth in SEQ ID NO:16.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2018
From: DIMITROV, DIMITER S.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 045073/0111 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2018
From: FENG, YANG
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 044671/0872 →
Continuity (5)
Division 14524304 · Oct 27, 2014
Continuation 13790881
Continuation In Part PCTUS2011050943 · Sep 9, 2011
Provisional Application 61381340 · Sep 9, 2010
Related Publication 20160207999A1 · Jul 21, 2016